http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106902116-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4545 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 |
| filingDate | 2017-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106902116-B |
| titleOfInvention | Application of rifamycin-quinolizidone dual-target molecule |
| abstract | The invention discloses application of a rifamycin-quinolizidone dual-target molecule shown as a formula I in inhibition of anaerobic flora. The rifamycin-quinolizinone double-target molecule disclosed by the invention has broad-spectrum antibacterial activity, has activity on anaerobic bacteria including most vaginal pathogenic bacteria, has in vitro antibacterial activity stronger than first-line antibacterial vaginosis medicines such as metronidazole and clindamycin, and has a good application prospect in the aspects of preventing and treating bacterial vaginosis or other related diseases caused by anaerobic bacteria. |
| priorityDate | 2017-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 28.